Agenus (NASDAQ:AGEN) Price Target Cut to $3.00 by Analysts at Robert W. Baird

Agenus (NASDAQ:AGEN) had its price objective lowered by stock analysts at Robert W. Baird from $6.00 to $3.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the biotechnology company’s stock. Robert W. Baird’s price target would indicate a potential upside of 46.34% from the company’s current price.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $8.75.

Agenus Trading Down 4.7 %

NASDAQ AGEN opened at $2.05 on Wednesday. The stock has a market cap of $48.09 million, a P/E ratio of -0.18 and a beta of 1.23. The company’s fifty day simple moving average is $3.24 and its 200-day simple moving average is $3.85. Agenus has a 52 week low of $1.93 and a 52 week high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to analysts’ expectations of $30.09 million. On average, research analysts expect that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AGEN. EP Wealth Advisors LLC bought a new position in shares of Agenus during the third quarter worth about $55,000. Corton Capital Inc. acquired a new stake in Agenus during the fourth quarter valued at approximately $36,000. Point72 DIFC Ltd raised its stake in Agenus by 380.0% during the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 11,542 shares in the last quarter. Virtu Financial LLC bought a new position in Agenus during the 4th quarter worth approximately $51,000. Finally, Apollon Wealth Management LLC acquired a new position in shares of Agenus in the 4th quarter worth approximately $55,000. 61.46% of the stock is owned by institutional investors and hedge funds.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.